Omega 3 fatty acid for prevention of sickle cell crisis
Not Applicable
Completed
- Conditions
- Sickle cell anaemia (HbSS)Haematological DisordersSickle-cell anaemia without crisis
- Registration Number
- ISRCTN80844630
- Lead Sponsor
- Mother and Child Foundation (UK)
- Brief Summary
2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/23193009 2013 results in: http://www.ncbi.nlm.nih.gov/pubmed/24095588 2013 results in: http://onlinelibrary.wiley.com/doi/10.1002/lite.201300308/abstract 2015 results in: http://www.ncbi.nlm.nih.gov/pubmed/25976467 2018 results in: https://www.ncbi.nlm.nih.gov/pubmed/30170260
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
1. HbSS phenotype
2. Male and female participants
3. Steady state
4. Aged 2 to 50 years old
Exclusion Criteria
1. Other phenotypes
2. Patients in crisis
3. Patients on hydroxyurea treatment
4. Presence of other chronic diseases
5. Blood transfusion in the previous four months
6. Pregnancy
7. Previous history of overt stroke
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br> 1. Annualised rates of clinical vaso-occlusive crisis is defined as painful events that lead to hospitalisation.<br> 1.1. Vaso-occlusive crisis is defined as a painful event characterised by musculoskeletal and/or visceral pain which is usually associated with mild pyrexia and the passage of dark or red urine.<br>
- Secondary Outcome Measures
Name Time Method <br> 1. Haemolytic crisis<br> 2. Rate of blood transfusion<br> 3. School attendance<br> 4. Hb level and mean cell volume (MCV)<br>